respiratori
tract
infect
rank
second
caus
adult
paediatr
morbid
mortal
worldwid
respiratori
tract
infect
caus
mani
diff
erent
bacteria
includ
mycobacteria
virus
rapid
detect
pathogen
individu
case
crucial
achiev
best
clinic
manag
public
health
surveil
control
outcom
challeng
improv
manag
outcom
respiratori
tract
infect
exist
rapid
identifi
cation
drug
resist
pathogen
widespread
surveil
infect
local
intern
global
respons
infect
pandem
potenti
develop
genom
amplifi
cation
led
discoveri
sever
new
respiratori
pathogen
sensit
pcr
method
diagnost
workup
avail
advanc
technolog
allow
develop
singl
multiplex
pcr
techniqu
provid
rapid
detect
respiratori
virus
clinic
specimen
microarraybas
multiplex
nucleicacidbas
deepsequenc
method
allow
simultan
detect
pathogen
nucleic
acid
multipl
antibiot
resist
provid
hope
revolutionis
rapid
point
care
respiratori
tract
infect
diagnost
respiratori
tract
infect
caus
mani
viral
bacteri
pathogen
second
common
caus
morbid
mortal
worldwid
lower
respiratori
tract
infect
come
second
global
burden
diseas
rank
ischaem
heart
diseas
surveil
report
europ
show
substanti
rise
number
infect
caus
antimicrobi
resist
bacteria
commun
acquir
pneumonia
hospitalacquir
pneumonia
ventil
associ
pneumonia
continu
present
clinic
signifi
cant
diagnost
manag
challeng
addit
worldwid
spread
multi
drug
resist
tuberculosi
emerg
multidrug
resist
gramneg
bacteria
eff
ectiv
therapi
option
exist
major
concern
respiratori
tract
infect
also
common
infect
ever
increas
number
immunocompromis
peopl
broader
diff
erenti
diagnosi
opportunist
microorgan
present
diagnost
challeng
success
treatment
outcom
respiratori
tract
infect
present
type
healthcar
set
achiev
rapid
sensit
specifi
c
identifi
cation
pathogen
antibiot
resist
profi
le
allow
eff
ectiv
evidencebas
antimicrobi
therapi
pathogenspecifi
c
infect
control
measur
presenc
microbi
nucleic
acid
respiratori
tract
sampl
exploit
amplifi
cation
target
identifi
microb
antibiot
resist
review
describ
avail
diagnost
test
viral
bacteri
caus
respiratori
tract
infect
million
adult
children
worldwid
continu
die
treatabl
respiratori
tract
infect
caus
wide
rang
microbi
pathogen
emerg
multiantibiot
resist
bacteria
novel
respiratori
virus
pandem
potenti
global
concern
optimum
clinic
manag
outcom
achiev
rapid
accur
diagnosi
microbi
caus
respiratori
tract
infect
initi
appropri
antibiot
therapi
presenc
microbi
nucleic
acid
respiratori
tract
sampl
exploit
amplifi
cation
microb
speci
antibiot
resist
specifi
c
genet
target
molecular
diagnost
platform
allow
rapid
diagnost
test
model
autom
platform
use
nucleic
acid
amplifi
cation
techniqu
naat
clinic
dilemma
surround
use
high
sensit
specifi
citi
naat
identifi
cation
pathogen
nucleic
acid
respiratori
tract
sampl
may
necessarili
attribut
causat
valid
naat
test
screen
respiratori
tract
infect
caus
specifi
c
viral
bacteri
group
use
diagnost
laboratori
diagnos
select
pathogen
usual
combin
tradit
method
laboratori
develop
countri
use
tradit
ageold
method
diagnosi
respiratori
tract
infect
except
cepheid
genexpert
mtbrif
assay
roll
worldwid
rapid
diagnosi
tuberculosi
rifampicin
resist
microarraybas
multiplex
nucleicacidbas
deepsequenc
method
simultan
detect
pathogen
nucleic
acid
multipl
antibiot
resist
provid
hope
revolutionis
rapid
pointofcar
tuberculosi
diagnost
invalu
identifi
new
viral
bacteri
pathogen
despit
advanc
great
need
rapid
pointofcar
pathogenspecifi
c
sensit
aff
ordabl
diagnost
remain
advanc
clinic
manag
infect
control
improv
public
health
respons
emerg
pathogen
develop
technolog
er
potenti
improv
qualiti
speed
tractabl
near
pointofcar
rapid
diagnost
test
patient
respiratori
tract
infect
present
point
care
diagnost
test
avail
simultan
diff
erenti
bacteri
includ
tuberculosi
viral
microbi
caus
achiev
best
possibl
treatment
outcom
present
patient
present
acut
respiratori
tract
infect
start
empir
antimicrobi
treatment
presum
acut
bacteri
infect
rather
therapi
direct
causal
organ
major
drawback
clinic
manag
respiratori
tract
infect
worldwid
nowaday
absenc
standardis
rapid
accur
specifi
c
pointofcar
diagnost
test
abl
screen
major
pathogen
group
enabl
identi
fi
cation
caus
organ
ascertain
anti
microbi
suscept
present
advanc
molecular
technolog
er
uniqu
opportun
address
unmet
need
new
lethal
virus
bacteria
caus
respiratori
tract
infect
sever
epidem
potenti
emerg
past
year
threaten
global
health
secur
attract
widespread
media
polit
attent
includ
sever
acut
respiratori
syndrom
corona
viru
sarscov
swineorigin
infl
uenza
middl
east
respiratori
syndrom
coronaviru
merscov
multi
drug
resist
extensivelydrug
resist
tuberculosi
pandrug
resist
gramposit
gramneg
bacteria
antivir
resist
cyto
megaloviru
strain
immunocompromis
patient
azoleresist
fungi
newli
emerg
respiratori
pathogen
threat
merit
close
monitor
expand
epidem
potenti
includ
avian
infl
uenza
infl
uenza
swine
variant
human
adenoviru
rhinoviru
group
c
caus
localis
outbreak
great
concern
whenev
previous
unknown
potenti
lethal
microorgan
caus
respiratori
tract
infect
emerg
clinician
microbiologist
public
health
offi
cial
expect
work
synergist
togeth
nation
global
health
system
respond
threat
respons
mani
compon
rapid
diagnosi
identifi
cation
similar
case
case
control
studi
determin
reservoir
mode
transmiss
risk
factor
collect
individu
case
cluster
data
report
ascertain
transmiss
pattern
isol
identifi
cation
characteris
specifi
c
pathogen
establish
koch
postul
possibl
develop
pathogenspecifi
c
diagnost
genom
sequenc
monitor
evolut
transmiss
pattern
collabor
activ
essenti
identifi
cation
specifi
c
microorgan
guidanc
appropri
target
therapi
monitor
respons
treatment
predict
prognosi
guidanc
infect
control
measur
public
health
surveil
control
recommend
rapid
accur
diagnost
laboratori
test
crucial
public
health
manag
respiratori
tract
infect
caus
new
potenti
lethal
pathogen
requir
ideal
pointofcar
nearpati
test
respiratori
tract
infect
similar
tabl
may
diff
er
accord
specifi
c
need
healthcar
set
sever
diagnost
platform
test
great
potenti
improv
manag
respiratori
tract
infect
furthermor
becom
increasingli
import
respons
outbreak
respiratori
tract
infect
caus
zoonot
pathogen
jump
speci
barrier
epidem
potenti
sever
commerci
diagnost
test
platform
incorpor
technolog
promis
substanti
reduc
turnaround
time
diagnosi
host
microbi
infect
includ
respiratori
tract
market
develop
tabl
typic
autom
semiautom
system
kit
integr
sampl
prepar
pathogen
detect
identifi
cation
antimicrobi
resist
gene
provid
autom
readout
result
test
platform
advanc
system
requir
least
possibl
user
input
throughout
process
capabl
detect
sever
pathogen
simultan
depend
test
singl
multipl
pathogen
antimicrobi
resist
may
detect
system
er
improv
speed
diagnosi
also
increas
sensit
detect
howev
develop
test
success
implement
clinic
practic
requir
develop
accuraci
result
high
multiplex
test
desir
characterist
provid
diagnost
epidemiolog
inform
becom
converg
routin
diagnost
laboratori
consid
fulfi
lling
public
health
role
molecular
multiplex
test
need
transport
outsid
laboratori
pointofcar
test
busi
tertiari
care
outpati
clinic
set
rural
area
develop
countri
point
basic
requir
method
may
diverg
fi
eld
studi
adopt
amplifi
cation
technolog
may
need
someth
suit
situat
power
suppli
guarante
isotherm
amplifi
cation
pointofcar
test
oper
simplic
allow
use
nonlaboratori
train
staff
accur
interpret
raw
signal
data
key
factor
advent
laboratori
test
practic
medicin
art
make
diagnosi
respiratori
infect
reli
entir
take
seri
medic
histori
physic
examin
discoveri
microscop
antoni
van
leeuwenhoek
fi
rst
step
toward
develop
laboratori
diagnost
test
respiratori
tract
infect
microscop
examin
stain
sputum
coupl
sputum
cultur
agar
follow
liquidcultur
method
refi
nement
bacteri
viral
cultur
method
improv
abil
detect
specifi
c
pathogen
identifi
suscept
test
specifi
c
antimicrobi
although
time
need
cultur
growth
h
infl
uenc
treatment
decis
admiss
diagnost
method
chang
late
major
advanc
molecular
biolog
immunolog
genom
technic
engin
led
mani
new
diagnost
test
serolog
test
detect
microbi
antigen
antibodi
agglutin
test
com
plement
fi
xation
test
fl
uoresc
antibodi
test
radio
immunoassay
elisa
develop
variou
pathogen
without
great
infl
uenc
clinic
manag
respiratori
tract
infect
point
care
relev
develop
use
nucleic
acid
amplifi
cation
techniqu
naat
respiratori
tract
infect
diagnost
presenc
microbi
nucleic
acid
respiratori
tract
sampl
sputum
nasopharyng
swab
tracheal
aspir
bronchoalveolar
lavag
exploit
amplifi
cation
microbespecifi
c
genet
target
initi
labour
intens
naat
technolog
evolv
real
time
pcr
rtpcr
loopmedi
amplifi
cation
lamp
nucleic
acid
sequencebas
amplifi
cation
strand
displac
amplifi
cation
latter
three
method
avoid
thermocycl
introduct
naat
mainstay
diagnosi
viral
respiratori
tract
infect
larg
base
serolog
consist
combin
detect
substanti
antibodi
rise
complementfi
xation
test
detect
viral
antigen
immuno
fl
uoresc
colorimetr
method
viru
isol
cell
cultur
often
blind
passag
follow
secondari
detect
immunofl
uoresc
haemadsorpt
older
gener
test
virus
still
use
today
scenario
time
result
crucial
past
two
decad
sensit
specifi
citi
test
detect
viral
respiratori
pathogen
improv
develop
genom
amplifi
cation
sever
new
respiratori
virus
multiplex
pcr
assay
identifi
sever
diff
erent
virus
singl
test
sever
multiplex
pcr
test
commerci
avail
constantli
refi
ned
assess
basic
laboratori
diagnosi
viral
caus
respiratori
tract
infect
coupl
subtyp
antivir
drug
resist
nucleotid
polymorph
togeth
viral
load
assay
provid
extens
inform
optimum
treatment
respiratori
tract
infect
clinic
use
test
determin
rel
degre
sensit
specifi
citi
time
taken
obtain
result
monoclonalantibodi
direct
fl
uoresc
antibodi
test
usual
adequ
specifi
citi
particular
viru
tradeoff
turnaround
time
sensit
thu
although
colorimetr
test
direct
antigen
detect
turnaround
time
less
hour
sensit
could
around
develop
reaction
chemistri
enabl
target
amplifi
cation
virus
reaction
keep
sensit
specifi
citi
high
turnaround
time
still
relev
clinic
need
avail
version
inhous
commerci
develop
multiplex
test
er
potenti
amplifi
cation
pathogen
clinic
sampl
although
turnaround
time
approach
whole
work
day
sever
headtohead
comparison
inhous
commerci
test
publish
advantag
multiplex
test
increas
chanc
identifi
microbi
caus
respiratori
tract
infect
detect
one
pathogen
singl
time
point
coinfect
diffi
culti
lie
interpret
fi
nding
relat
patient
clinic
statu
detect
weak
signal
one
viru
may
repres
commens
tailend
previou
infect
although
may
also
show
infect
recent
evolv
anoth
possibl
weaker
signal
pronounc
viral
infect
lower
respiratori
tract
viru
yet
well
repres
upper
respiratori
tract
diff
erent
viral
infect
present
issu
clinic
sampl
gener
highest
diagnost
yield
also
depend
pathogenesi
viru
rapid
develop
multiplex
test
may
outstrip
clinic
need
rather
provid
clinician
use
inform
clinic
interpret
decis
make
might
becom
complex
demonstr
challeng
interpret
viru
identifi
cation
multiplex
pcr
shown
prospect
studi
neonat
intens
care
unit
year
although
morbid
outcom
associ
respiratori
viru
infec
tion
infect
also
commonli
detect
absenc
clinic
ill
despit
advanc
technolog
gold
standard
diagnost
techniqu
respiratori
tract
infect
bacteri
caus
tradit
cultur
follow
identifi
cation
antimicrobi
suscept
test
variou
manual
autom
method
individu
diagnost
laboratori
may
use
molecular
method
develop
either
inhous
extern
part
detect
process
supplementari
method
often
aim
organ
diffi
cult
take
long
time
cultur
bordetella
pertussi
legionella
pneumophila
mycoplasma
pneumonia
chlamydophila
pneumonia
laboratori
diagnosi
specifi
c
bacteri
caus
respiratori
tract
infect
notori
diffi
cult
goldstandard
cultur
test
identifi
caus
exist
unknown
pathogen
poor
accuraci
sensit
rapid
molecular
diagnost
assay
base
detect
nucleic
acid
er
potenti
solut
problem
accur
comprehens
detect
antimicrobi
resist
techniqu
fraught
diffi
culti
owe
multitud
antimicrobi
resist
determin
exist
limit
capabl
multiplex
pcrbase
technolog
despit
appar
develop
activ
area
platform
test
market
clinic
evalu
test
publish
tabl
licens
genexpert
test
bacteri
lower
respiratori
tract
infect
exist
although
studi
report
use
platform
detect
aureu
respiratori
sampl
studi
examin
endotrach
aspir
suspect
ventil
associ
pneumonia
show
presenc
gramposit
cocci
microscopi
compar
result
qualit
quantit
tradit
cultur
although
research
report
good
specifi
citi
compar
qualit
cultur
microscopi
perform
poorli
compar
quantit
cultur
present
laboratori
report
quantit
result
gener
defi
ne
count
colonyform
unitsml
signifi
cant
infect
lower
count
presum
show
colonis
contamin
convent
whole
genom
sequenc
wg
requir
prior
knowledg
pathogen
wherea
next
gener
sequenc
ng
method
sequenc
genom
materi
present
sampl
ng
abil
sequenc
mani
microbi
genom
deliv
interpret
result
sequenc
inform
near
realtim
thu
ng
provid
unbias
approach
detect
pathogen
present
clinic
sampl
antibiot
resist
gene
new
pathogen
discoveri
ng
method
provid
sensit
multiplex
capabl
er
mani
potenti
advantag
diagnost
microbiolog
laboratori
rapid
detect
drug
resist
time
identifi
cation
nosocomi
transmiss
rang
bacteri
viral
pathogen
therefor
convent
method
poor
detect
lowlevel
drug
resist
mutat
contribut
phenotyp
antimicrobi
antivir
resist
need
amplicon
limit
length
sequenc
thu
use
sanger
method
pathogen
genotyp
outbreak
ng
method
har
sequenc
multipl
diff
erent
pathogen
singl
sampl
multipl
sampl
run
barcod
technolog
label
sampl
uniqu
identifi
er
use
simultan
sequenc
multipl
sampl
patient
infect
pathogen
sever
develop
need
use
ng
becom
widespread
improv
sensit
pathogen
sequenc
directli
clinic
materi
develop
tractabl
softwar
practic
use
method
obviat
necess
prior
cultur
pcr
amplifi
cation
enrich
target
pathogen
need
european
fund
consortium
pathseek
investig
high
multipl
multiplex
multiplex
mani
diff
erent
pathogen
reaction
use
ng
method
bespok
softwar
sequenc
whole
pathogen
genom
includ
infl
uenza
tuberculosi
directli
clinic
materi
altern
approach
retain
unbias
natur
ng
opt
instead
unselect
deep
sequenc
rna
transcript
isol
clinic
materi
therebi
captur
rna
dna
pathogen
discov
new
agent
advent
nano
technolog
nanopor
sequenc
mobil
devic
promis
rapid
turnaround
time
small
footprint
decreas
cost
bring
us
closer
possibl
nearpati
pathogen
genom
sequenc
data
interpret
avail
within
near
futur
contrast
sanger
method
ng
abl
gener
sequencedata
per
run
detect
multipl
resist
mutat
simultan
even
occur
noncontigu
gene
ng
method
sequenc
longer
region
singl
assay
includ
whole
pathogen
genom
particularli
power
phylogenet
analys
identifi
pathogen
transmiss
outbreakmonitor
although
mani
diff
erent
ng
methodolog
avail
principlesnam
unbias
sequenc
popu
lation
librari
amplifi
ed
dnatempl
molecul
common
pathogen
advanc
next
gener
method
includ
pacbio
nanopor
sequenc
singl
molecul
provid
read
length
thousand
base
long
throughput
higher
overal
error
rate
ng
method
har
sequenc
multipl
diff
erent
pathogen
singl
sampl
multipl
sampl
run
challeng
identifi
cation
antimicrobi
resist
particularli
complex
multi
drug
resist
organ
rapidli
assembl
analys
gener
data
requir
construct
robust
databas
data
analysi
algorithm
rapidli
equat
genom
like
antimicrobi
resist
profi
le
mer
newli
describ
human
diseas
predominantli
aff
ect
respiratori
tract
fi
rst
report
saudi
arabia
septemb
identifi
cation
merscov
novel
betacoronaviru
patient
jeddah
die
sever
respiratori
ill
subsequ
sever
commun
hospitalbas
studi
defi
ned
epidemiolog
transmiss
dynam
spectrum
clinic
present
mild
sever
includ
relationship
rapidli
fulmin
diseas
comorbid
medic
disord
casecontrol
studi
popul
aff
ect
countri
urgent
need
examin
spread
preval
transmiss
merscov
wg
use
studi
viral
transmiss
evolut
sever
studi
base
nucleic
acid
detect
assay
found
close
relat
coronavirus
diff
erent
speci
bat
africa
saudi
arabia
north
america
comparison
pcr
serolog
method
livestock
anim
merscov
show
dromedari
camel
harbour
merscov
neutralis
antibodi
fi
nding
verifi
ed
studi
camel
farm
human
mer
rtpcrconfi
rmed
case
occur
report
show
ident
merscov
sequenc
obtain
patient
die
laboratoryconfi
rmed
mer
obtain
dromedari
camel
rhinorrhoea
patient
contact
estim
million
world
million
case
pulmonari
tuberculosi
diagnos
thu
still
untreat
continu
spread
diseas
commun
estim
case
multidrug
resist
tuberculosi
worldwid
undiagnos
patient
pulmonari
tuberculosi
present
respiratori
symptom
receiv
repeat
cours
antibiot
screen
tuberculosi
continu
use
centuryold
sputum
microscopi
time
requir
tradit
culturebas
diagnosi
mycobacterium
tuberculosi
coupl
larg
global
health
burden
associ
mortal
tuberculosi
led
focus
global
eff
ort
new
rapid
sensit
tuberculosi
diagnost
tabl
past
year
seen
unpreced
activ
develop
rang
new
diagnost
test
base
cultur
molecular
nonmolecular
method
score
smalltomedium
size
enterpris
major
concern
market
test
assess
rigor
diagnost
accuraci
robust
oper
condit
fi
eld
costeff
ectiv
practic
use
new
pointofcar
nearpati
innov
tuberculosi
diagnost
sever
target
rapid
diagnosi
tuberculosi
identifi
cation
rifampicin
resist
xpert
mtbrif
assay
identifi
cation
multidrug
resist
tuberculosi
hain
genotyp
multidrug
resist
plu
system
routin
prospect
variabl
number
tandem
repeatsmycobacteri
interspers
repetit
unit
vntrmiru
type
allow
prioritis
case
contact
trace
xpert
mtbrif
assay
use
cepheid
genexpert
system
forerunn
rapid
molecular
pointofcar
diagnost
result
sputum
analysi
avail
h
oper
within
h
numer
assess
studi
sever
point
care
shown
assay
sensit
specifi
c
increas
detect
smearneg
patient
pulmonari
tuberculosi
tabl
howev
diagnost
improv
alway
lead
better
clinic
outcom
randomis
multicentr
trial
clinic
outcom
xpert
mtbrif
assay
although
high
proport
patient
start
treatment
day
present
signifi
cant
improv
lower
tuberculosi
relat
morbid
research
suggest
lack
benefi
result
eff
ectiv
empir
manag
control
group
promis
test
platform
introduc
detect
tuberculosi
align
improv
function
point
care
increas
accuraci
detect
develop
drug
resist
target
although
tuberculosiscentr
diagnost
test
develop
import
prudent
realis
might
fi
longer
term
goal
optimum
converg
deliveri
health
care
non
communic
communic
diseas
move
away
diseasespecifi
c
silo
although
genotyp
analysi
drugresist
strain
tuberculosi
possibl
limit
laboratori
method
exist
faster
accur
determin
antimicrobi
resist
phenotyp
need
overcom
direct
sequenc
sputum
requir
prior
pathogen
enrich
cultur
enrich
method
microarraybas
multi
plex
nucleicacidbas
deep
sequenc
method
simultan
detect
tuberculosi
dna
multipl
drug
resist
sever
fi
rstline
secondlin
tuberculosi
drug
provid
hope
revolutionis
rapidpointofcar
tuberculosi
diagnost
next
gener
benchtop
sequenc
system
potenti
allow
tuberculosi
sequenc
resist
fi
rstline
secondlin
tuberculosi
drug
direct
sputum
could
overcom
problem
low
bacteri
load
sputum
provid
timescal
week
quicker
culturebas
resist
test
also
need
comprehens
map
antimicrobi
resist
mutat
bespok
softwar
easi
interpret
resist
assay
wg
approach
link
quantit
bacteriolog
gener
comprehens
genotypephenotyp
correl
across
multidrug
resist
tuberculosi
isol
provid
opportun
extract
genom
data
exploit
develop
pointofcar
diagnost
test
coupl
drug
resist
screen
epidemiolog
public
health
control
purpos
sever
manufactur
develop
potenti
relev
diagnost
technolog
begin
enter
market
need
improv
understand
role
individu
microorgan
respiratori
diseas
true
relationship
pathogen
quantiti
diseas
major
challeng
implement
molecular
test
technolog
abil
test
distinguish
microbi
colonis
seri
infect
diseas
causat
standard
laboratori
cultur
gener
incud
quantit
element
usual
cutoff
cfuml
respiratori
tract
specimen
invari
contamin
colonis
organ
nasopharynx
increas
sensit
molecular
techniqu
detect
colonis
addit
multipl
pathogen
speci
present
one
specimen
extent
repres
genuin
coinfect
oppos
mixtur
infect
colonis
need
determin
diffi
culti
distinguish
infect
colonis
creat
dilemma
whether
result
use
guid
treatment
incorpor
quantit
element
diagnost
use
quantit
pcr
go
way
toward
improv
interpret
present
biggest
technolog
gap
exist
within
diagnosi
lower
respiratori
tract
infect
focu
consortia
partnership
fund
eu
innov
medicin
initi
pathseek
rapid
identifi
cation
respiratori
tract
infect
ridrti
develop
rapid
pointofcar
test
platform
infecti
diseas
rappid
aim
ridrti
consortium
develop
rapid
samplein
answerout
nucleicacidbas
platform
diagnosi
type
pneumonia
commun
acquir
pneumonia
hospitalacquir
pneumonia
ventil
associ
pneumonia
caus
viral
bacteri
pathogen
rappid
propos
use
variou
technolog
develop
pointofcar
test
infl
uenza
ventil
associ
pneumonia
commun
acquir
pneumonia
search
articl
publish
english
pubm
embas
cochran
databas
googl
scholar
public
websit
term
respiratori
tract
lung
infect
combin
term
diagnost
diagnost
test
diagnost
platform
pcr
serolog
rapid
molecular
antibiot
resist
sequenc
point
care
develop
period
march
june
substant
review
identifi
ed
subject
referenc
good
qualiti
pointofcar
product
diagnosi
respiratori
tract
infect
hope
expect
avail
market
next
year
develop
naat
test
progress
coanalys
sever
viral
bacteri
target
possibl
fulli
autom
multiplex
naat
test
genexpert
nanospher
filmarray
suitabl
low
throughput
scenario
although
nanospher
technolog
modest
scaleup
possibl
addit
process
modul
batch
process
valid
naat
test
diagnos
pathogen
usual
done
combin
tradit
microbiolog
method
futur
threepoint
arrang
costeff
ectiv
rapid
diagnosi
respiratori
tract
infect
might
possibl
fi
rst
point
low
throughput
fulli
autom
naat
platform
situat
pointofcar
test
primarycar
secondarycar
emerg
area
test
done
clinic
staff
provid
outofhour
diagnost
inform
manag
admiss
patient
infect
control
practic
second
stage
robust
inhous
commerci
naat
test
larg
batch
size
provid
main
diagnost
laboratori
capac
manag
signifi
cant
vari
rang
target
respiratori
tract
infect
request
gener
within
secondari
care
set
third
point
yet
well
establish
diagnost
pathway
pathogendiscoveri
process
form
initi
nontarget
amplifi
cation
polyadenyl
rna
clinic
sampl
arraybas
select
potenti
pathogen
sequenc
captur
structur
might
much
longer
turnaround
time
would
provid
fi
nal
opportun
obtain
diagnosi
result
could
obtain
via
fi
rst
second
point
threepoint
diagnost
process
would
provid
maximum
opportun
obtain
relev
diagnost
inform
fi
rst
fulli
autom
naat
platform
earli
stage
commercialis
platform
prove
success
like
rapidli
adopt
healthcar
system
worldwid
howev
third
socal
pathogendiscoveri
approach
yet
develop
clinic
use
might
time
propos
scenario
becom
realiti
use
autom
reliabl
improv
facilit
test
laboratori
toward
interfac
patient
clinician
point
care
ideal
rural
area
develop
countri
run
solar
power
sever
technolog
advanc
show
great
promis
although
substanti
progress
made
develop
new
pathogenspecifi
c
rapid
diagnost
test
issu
interpret
sensit
specifi
citi
need
resolv
clinic
dilemma
surround
use
high
sensit
specifi
citi
naat
identifi
cation
pathogen
nucleic
acid
respiratori
tract
sampl
might
necessarili
attribut
causat
practic
manag
term
patient
respiratori
tract
infect
point
care
rapid
diagnost
test
need
singl
respiratori
tract
sampl
distinguish
bacteri
viral
infect
identifi
bacteria
speci
level
delin
antibiot
sensit
test
would
enabl
prompt
initi
pathogenspecifi
c
treatment
enabl
prompt
modifi
cation
empir
antibiot
therapi
thu
improv
manag
outcom
patient
present
respiratori
tract
infect
new
test
wide
adopt
possibl
power
solar
energi
use
reagent
requir
cold
chain
storag
az
wrote
coordin
seri
paper
develop
draft
outlin
contribut
section
fi
nalis
manuscript
author
contribut
relev
text
tabl
expert
section
contribut
fi
nalis
manuscript
az
princip
investig
vg
coprincip
investig
eu
grant
ridrti
jb
princip
investig
eu
grant
pathseek
author
declar
compet
interest
